

CUREVAC NV

ISIN: NL0015436031

WKN: N2451R105

Asset Class: **Stock**

Company

2024/07/17 22:00:00



Price

3.65 USD

Difference ▲ 2.53%(0.09)



Contact Details

CUREVAC NV

Tel: +49-7071-9883-0

--

Fax: +49-7071-9883-1101

Friedrich-Miescher-Strasse 15 Web: <http://www.curevac.com>

72076 Tübingen

E-mail: info@curevac.com

Company Profile

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	528,443,000		623,304,000		1,068,989,000	
Common stock capital		29,691,000		24,973,000		25,534,000
Fixed assets	342,295,000		295,033,000		248,163,000	
Equity capital of a company		571,038,000		569,114,000		782,934,000
Cash and cash equivalents	444,568,000		529,139,000		922,796,000	
Accrued liabilities		0		65,443,000		0
Other assets	-		-		-	
Current liabilities		205,894,000		166,731,000		406,815,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		93,805,000		182,493,000		127,402,000
Different income		-		-		-
Other liabilities		53,133,000		77,448,000		98,491,000
Total assets	870,739,000	870,739,000	918,338,000	918,338,000	1,317,152,000	1,317,152,000

Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	1,172	1,049	884
Equity ratio	65.58%	61.97%	59.44%
Debt-equity ratio	52.48%	61.36%	68.23%

Others

	2023	2022	2021
Tax Expense Rate	-0.08%	0.05%	0.19%

Income statement

	2023	2022	2021
Turnover	58,118,000	70,856,000	121,732,000
Net income	-281,270,000	-261,723,000	-486,640,000
EBIT	-272,022,030	-240,569,853	-447,134,552
Operating income before taxes	-281,056,000	-261,855,000	-487,564,000
Cash Flow	-289,616,000	-300,764,000	-866,543,000
Net interest income	15,392,000	317,000	-277,000
Research and development expenses	115,879,000	56,647,000	959,352,000
Income taxes	214,000	-132,000	-924,000
Result from investments in subsidiaries, associates and other	0	0	0
Revenues per employee	45,503	61,981	126,359

Board of Directors

Baron Jean Stéphenne	Chairman of Supervisory Board
Debra Stephanie Barker	Member of Supervisory Board
Klaus Schollmeier	Member of Supervisory Board
Mathias Hothum	Member of Supervisory Board
Viola Bronsema	Member of Supervisory Board
Birgit Hofmann	Member of Supervisory Board
Craig Tooman	Member of Supervisory Board
Michael Brosnan	Member of Supervisory Board

Members of Management Board

Alexander Zehnder	Chairman of Managing Board
Malte Greune	Member of Executive Committee
Myriam Mendila	Member of Executive Committee
Pierre Kemula	Member of Executive Committee
Thaminda Ramanayake	Member of Executive Committee